Sarepta Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Sarepta Therapeutics has a total shareholder equity of $859.3M and total debt of $1.2B, which brings its debt-to-equity ratio to 144.1%. Its total assets and total liabilities are $3.3B and $2.4B respectively.
Key information
144.1%
Debt to equity ratio
US$1.24b
Debt
Interest coverage ratio | n/a |
Cash | US$1.68b |
Equity | US$859.34m |
Total liabilities | US$2.41b |
Total assets | US$3.26b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: S1RP34's short term assets ($2.6B) exceed its short term liabilities ($653.7M).
Long Term Liabilities: S1RP34's short term assets ($2.6B) exceed its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: S1RP34 has more cash than its total debt.
Reducing Debt: S1RP34's debt to equity ratio has increased from 40.7% to 144.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: S1RP34 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if S1RP34 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.